Abiomed - ABMD Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Abiomed in the last year. There are currently 1 sell rating and 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ABMD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ABMD, but not buy additional shares or sell existing shares.
View ABMD analyst ratings or view top-rated stocks.

3 Wall Street analysts have issued 12-month price objectives for Abiomed's stock. Their ABMD share price forecasts range from $235.00 to $355.00. On average, they anticipate the company's stock price to reach $311.25 in the next year. This suggests a possible upside of 18.7% from the stock's current price.
View analysts price targets for ABMD or view top-rated stocks among Wall Street analysts.

Abiomed's stock was trading at $359.17 at the start of the year. Since then, ABMD stock has decreased by 27.0% and is now trading at $262.25.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 27th 2022.
View our ABMD earnings forecast.

Abiomed, Inc. (NASDAQ:ABMD) released its quarterly earnings results on Thursday, August, 4th. The medical equipment provider reported $1.25 EPS for the quarter, beating the consensus estimate of $1.08 by $0.17. The medical equipment provider had revenue of $277.15 million for the quarter, compared to the consensus estimate of $276.46 million. Abiomed had a net margin of 20.60% and a trailing twelve-month return on equity of 14.33%. The business's revenue was up 9.7% on a year-over-year basis. During the same period in the previous year, the firm posted $1.10 earnings per share.
Read the conference call transcript.

Abiomed issued an update on its FY 2023 earnings guidance on Thursday, August, 18th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.13 billion-$1.17 billion, compared to the consensus revenue estimate of $1.18 billion.

96 employees have rated Abiomed Chief Executive Officer Michael R. Minogue on Glassdoor.com. Michael R. Minogue has an approval rating of 72% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Abiomed investors own include NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Align Technology (ALGN), Arista Networks (ANET), Intuitive Surgical (ISRG), Block (SQ), Netflix (NFLX), Adobe (ADBE) and Salesforce (CRM).

Abiomed trades on the NASDAQ under the ticker symbol "ABMD."

Abiomed's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Wedmont Private Capital (0.00%). Insiders that own company stock include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Joseph Riccelli, Magdalena Yesil, Marc A Began, Martin P Sutter, Michael R Minogue, Michael R Minogue, Paul Thomas and Todd A Trapp.
View institutional ownership trends.

Shares of ABMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ABMD stock can currently be purchased for approximately $262.25.

Abiomed (NASDAQ:ABMD) has a market capitalization of $11.97 billion and generates $1.03 billion in revenue each year. The medical equipment provider earns $136.51 million in net income (profit) each year or $4.74 on an earnings per share basis.

The company employs 2,003 workers across the globe.

Abiomed's mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The official website for the company is www.abiomed.com. The medical equipment provider can be reached via phone at (978) 646-1400, via email at ir@abiomed.com, or via fax at 978-777-8411.